Featured Story

Pharma's budding opportunity

Why the industry is forming bonds with CBD

PM1906 WebLeadImage 295X269 1

No single molecule has likely ever generated as much buzz in the wellness market as CBD.Cannabidiol — commonly known as CBD — is one of the primary, non-psychoactive compounds found in the cannabis plant. A recent loosening of regulations for CBD has triggered an explosion of over-the-counter dietary supplements touting so many therapeutic uses for the molecule, it almost sounds magical.Not long ago, cannabis products were widely viewed as a threat to the pharma industry, partly because of the competition they could pose within key therapeutic areas such as pain management. But these days, the smoky cloud of suspicion around marijuana and its derivatives has begun to…

Full Story

Pharma Manufacturing Exclusives


Valuable educational content — from tutorials to reference guides —  for all pharmaceutical manufacturing professionals.

Research Zone

A collection of news stories highlighting advances in medical science and pharmaceutical R&D.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Product Focus: Advancing aseptic processing

    By Meagan Parrish, Senior Editor

    While pharma has made tremendous strides in aseptic processing, the industry still struggles with contamination issues — indicating there is more work to be done. Like all segments of the pharma industry, aseptic manufacturing continues to be transformed by disruptive technologies. With the goals…

    Full Story
  • Biosimilars are coming to LATAM

    By Franco A. Cucchiaro, International Trade and Supply Chain Pharma Specialist

    If you’re a Game of Thrones fan, for many years you’ve heard that “winter is coming.” When it comes to biosimilars, it seems that we are finally facing it. More or less a decade ago, biosimilars were the incoming future, and now, across the globe, we can decisively say, that future is…

    Full Story
  • The top 5 new drugs bound for blockbuster status

    By Meagan Parrish, Senior Editor

    In the past few years, the FDA has set its sights on fast-tracking scores of new medications to more quickly and efficiently get needed treatments on the market. All told, the agency approved 59 new molecular entities in 2018 — a significant jump from the 47 approvals in 2017. Among the…

    Full Story
  • Will product drift cause a rift?

    By Ha Kung Wong, Partner, Venable Fitzpatrick’s Intellectual Property Litigation Practice

    The U.S. is still in the nascent stages of biosimilars. In fact, the U.S. Food and Drug Administration (FDA) is so concerned about promoting biosimilars that they released a Biosimilars Action Plan (BAP) in July 2018 to better clarify how companies can obtain approval and to educate the public.

    Full Story
  • Perfecting CAPA

    By Patterson Shafer Managing Director, Healthcare and Life Sciences, Grant Thornton

    Many years ago, while working on developing a Quality Management System for a large automotive company, we heard a story about how the company had perfected Corrective Action, Preventive Action (CAPA). The company had a clearly defined, cross-functional process with a very useful quality tool kit…

    Full Story
  • Enhancing the Paragraph IV Patent Certifications List database

    By Pharma Manufacturing staff

    Under the FDA’s Drug Competition Action Plan (DCAP), FDA committed to enhancing efficiency of the development and approval of ANDAs, with the ultimate goal of more approvals to help increase access to high-quality, lower cost generic drugs. The agency believes that additional information…

    Full Story

Latest Products